Molecular pathogenesis, recognition and Solidarity Therapeutic Approaches against COVID-19

A novel Corona Virus infection (COVID-19) is alike to viral pneumonia and it is caused by severe acute respiratory syndrome Corona Virus-2 (SARS-CoV-2). In this short review we discuss here common features of highly contagious and pathogenic SARS-CoV-2 provide current information of molecular immune pathogenesis, diagnosis and solidarity treatment of COVID-19 on the base of present perceptive of SARS-CoV infectivity, which may be useful to control and to combat pandemic situation.The pressure COVID-19 puts on health systems means that WHO considered the need for speed and scale in the trial. Whereas randomized clinical trials usually take years to design and conduct, the Solidarity Trial will reduce the time taken by 80%. Enrolling patients in one solitary randomized trial will help facilitate the rapid worldwide comparison of unproven treatments. This will conquer the hazard of multiple small trials not generating the strong evidence needed to determine the relative effectiveness of potential treatments.